Patents by Inventor Jasper Dingemanse

Jasper Dingemanse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
    Patent number: 11834443
    Abstract: The present invention relates to a crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol.
    Type: Grant
    Filed: July 1, 2022
    Date of Patent: December 5, 2023
    Assignee: Idorsia Pharmaceuticals Ltd
    Inventors: Cyrille Lescop, Jasper Dingemanse, Andreas Krause
  • Dosing regimen for a selective S1Preceptor agonist
    Patent number: 11771683
    Abstract: The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one.
    Type: Grant
    Filed: November 5, 2020
    Date of Patent: October 3, 2023
    Assignee: Actelion Pharmaceuticals Ltd
    Inventors: Jasper Dingemanse, Matthias Hoch, Andreas Krause
  • Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenox
    Patent number: 11390615
    Abstract: The present invention relates to a crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: July 19, 2022
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Cyrille Lescop, Jasper Dingemanse, Andreas Krause
  • Dosing regimen for a selective S1Preceptor agonist
    Patent number: 10857134
    Abstract: The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: December 8, 2020
    Assignee: ACTELION PHARMACEUTICALS LTD
    Inventors: Jasper Dingemanse, Matthias Hoch, Andreas Krause
  • Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
    Patent number: 10836754
    Abstract: The present invention relates to a crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: November 17, 2020
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Cyrille Lescop, Jasper Dingemanse, Andreas Krause
  • Dosing regimen for a selective S1Pagonist
    Patent number: 10660880
    Abstract: The present invention relates to a dosing regimen for a selective S1P1 receptor agonist, whereby the selective S1P1 receptor agonist is administered to a subject in such a way that during the initial treatment phase the selective S1P1 receptor agonist is administered at a dose which induces desensitization of the heart wherein said dose is below the target dose, and at a dosing frequency that sustains desensitization of the heart, until no further acute heart rate reduction occurs, followed by dose up-titration to the target dose of the selective S1P1 receptor agonist.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: May 26, 2020
    Assignee: ACTELION PHARMACEUTICALS LTD
    Inventors: Patrick Brossard, Jasper Dingemanse, Oliver Nayler, Michael Scherz, Beat Steiner
  • Dosing regimen for a selective S1Preceptor agonist
    Patent number: 10251867
    Abstract: The present invention relates to a dosing regimen for a selective S1P1 receptor agonist, whereby the selective S1P1 receptor agonist is administered to a subject in such a way that during the initial treatment phase the selective S1P1 receptor agonist is administered at a dose which induces desensitization of the heart wherein said dose is below the target dose, and at a dosing frequency that sustains desensitization of the heart, until no further acute heart rate reduction occurs, followed by dose up-titration to the target dose of the selective S1P1 receptor agonist.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: April 9, 2019
    Assignee: ACTELION PHARMACEUTICALS LTD.
    Inventors: Patrick Brossard, Jasper Dingemanse, Oliver Nayler, Michael Scherz, Beat Steiner
  • Dosing regimen for a selective S1Preceptor agonist
    Patent number: 10220023
    Abstract: The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: March 5, 2019
    Assignee: ACTELION PHARMACEUTICALS LTD
    Inventors: Jasper Dingemanse, Matthias Hoch, Andreas Krause
  • DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONIST
    Publication number: 20140315964
    Abstract: The present invention relates to a dosing regimen for a selective S1P1 receptor agonist, whereby the selective S1P1 receptor agonist is administered to a subject in such a way that during the initial treatment phase the selective S1P1 receptor agonist is administered at a dose which induces desensitization of the heart wherein said dose is below the target dose, and at a dosing frequency that sustains desensitization of the heart, until no further acute heart rate reduction occurs, followed by dose up-titration to the target dose of the selective S1P1 receptor agonist.
    Type: Application
    Filed: July 2, 2014
    Publication date: October 23, 2014
    Inventors: PATRICK BROSSARD, Jasper Dingemanse, Oliver Nayler, Michael Scherz, Beat Steiner
  • Dosing regimen for a selective S1P1 receptor agonist
    Patent number: 8785484
    Abstract: The present invention relates to a dosing regimen for a selective S1P1 receptor agonist, whereby the selective S1P1 receptor agonist is administered to a subject in such a way that during the initial treatment phase the selective S1P1 receptor agonist is administered at a dose which induces desensitization of the heart wherein said dose is below the target dose, and at a dosing frequency that sustains desensitization of the heart, until no further acute heart rate reduction occurs, followed by dose up-titration to the target dose of the selective S1P1 receptor agonist.
    Type: Grant
    Filed: March 12, 2009
    Date of Patent: July 22, 2014
    Assignee: Actelion Pharmaceuticals Ltd
    Inventors: Patrick Brossard, Jasper Dingemanse, Oliver Nayler, Michael Scherz, Beat Steiner
  • DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONIST
    Publication number: 20110021581
    Abstract: The present invention relates to a dosing regimen for a selective S1P1 receptor agonist, whereby the selective S1P1 receptor agonist is administered to a subject in such a way that during the initial treatment phase the selective S1P1 receptor agonist is administered at a dose which induces desensitization of the heart wherein said dose is below the target dose, and at a dosing frequency that sustains desensitization of the heart, until no further acute heart rate reduction occurs, followed by dose up-titration to the target dose of the selective S1P1 receptor agonist.
    Type: Application
    Filed: March 12, 2009
    Publication date: January 27, 2011
    Applicant: ACTELION PHARMACEUTICALS LTD
    Inventors: Patrick Brossard, Jasper Dingemanse, Oliver Nayler, Michael Scherz, Beat Steiner